
Index

- ability to pay 262, 407, 426–8, 432
accidents 7, 11, 30
 see also traffic deaths
ACE inhibitors 116, 118
Adam, T. 46–57, 523
addiction 60, 62
 see also drug use
ADHD 299, 303
adolescence *see* young people
adult day care 309
adult mortality 7–10, 308–9, 516
adverse selection 144, 345–6, 348
 health insurance 103, 114–15, 139, 141, 144
advertising, direct to consumer (DCA) 329–36
 agency relationships 330–31, 333
 care-seeking effect 330
 chronic illness and 331
 consumer reaction 332, 334
 historical background 329–30
 impact of 333
 literature 330–31, 332–6
 Medicaid/Medicare 336
 moral hazard 330, 335
 prescribing patterns 333
 price elasticity 333
 provider attitudes 330–31
Afghanistan, contracting-out 252, 255–6
Africa
 contracting-out 252
 internet access 168
 public health interventions 48, 49, 54, 56
age factor
 distributional judgements 408–9, 411, 421
 older workers 24–32, 290
 risk adjustment and 289, 290, 292
ageing 12, 17, 171, 395, 421
 disability and 321, 324–5
 drug subsidies 115, 534
 income and 11, 18, 126
 informal care 318–25
 mortality and 308–9
 nursing homes 307–14
 see also retirement
agency theory 271–3, 341, 416
AIDS *see* HIV/AIDS
Albania
 GATS commitments 167
 unofficial payments 155, 167
Al-Janabi, H. 415–22
alcohol use 5, 36, 299, 444
 cost-effectiveness analysis 516–20, 521, 524–5
 legal drinking age 81–2
 young people 60, 62–4, 65, 66, 67
 zero tolerance laws 66–7
altruism 62, 259, 343, 429
 health insurance and 93, 99, 123, 125
 incentives 241, 244, 286, 298
 informal care 320, 322
Alzheimer's disease 388
ambulance services 354, 429, 431
amphetamines 83
anthropometric records 48, 49
antibiotics 172, 589
Antigua and Barbuda, GATS commitments 167
antimicrobials 53
antipsychotic medication 310
antiretrovirals 486, 505, 511, 512
'any willing provider' 233–4, 237
Argentina
 child mortality 51
 unofficial payments 158
Armenia 154
 GATS commitments 167
Arrow, K.J. 95–6, 103, 127, 242, 280, 427
arthritis 117, 331, 383
Asia (equity in health/health care systems) 203–14
 benefit incidence analysis 207–9
 delivery/equity performance 212–13
 empirical analysis 203–4
 empirical evidence 204–12
 equity in health care utilization 205–7
 Equitap study 206, 207–8, 209–11
 ETEN 205
 Europe and (comparisons) 211–12
 financing 209, 212–13
 future agenda 213–14
 high-income countries 203, 205–9
 inequalities in health status 204–5
 low-/middle-income countries 204, 205–9, 211–12, 213–14
 poverty impact of expenditures 209–11, 213
 private financing 212

- rent-seeking 213
- social insurance systems 212
- tax systems 212–13
- transition economies 213
 - see also individual countries*
- Asian Development Bank 254
- assisted living 309
- asthma 76, 119, 278, 299, 391
- Auld, M.C. 36–44, 66, 149, 151
- Australia
 - capability approach 417
 - capitation in primary care 283
 - child mortality 51
 - cost-effectiveness analysis 530, 534
 - drug-related crime 81, 83
 - drug insurance plan 118
 - drugs price bargaining 235
 - GATS commitments 167
 - health care use 147
 - health services trade 167, 169, 171
 - patient cost sharing 118
 - PBAC 592
 - PBMA 577
 - pharmaceutical evaluation 443, 463–4, 534, 586, 587, 590, 592
 - physician fee response 276
 - priority setting 577
 - temporary movement of providers 171
- Austria
 - child mortality 50
 - GATS commitments 167
 - hospital competition 226
 - older workers 31
- back problems 10, 42, 373, 377
- bandwagon effect 61
- Bangladesh 53
 - child health and maternal services 207
 - child mortality 205
 - contracting-out 252, 254–5
 - equity in health care 204, 205, 206–7
 - government social spending 207, 208
 - health care financing 210
 - health care utilization 206
 - health inequalities 204
 - poverty and health expenditure 210–11
 - tax and direct payments 213
 - temporary movement of providers 171
 - unofficial payments 155, 157
- Barbados, GATS commitments 167
- bargaining *see* negotiation and bargaining in health care
- Barros, P.P. 231–7, 285
- Basu, A. 38, 43, 151, 415, 464, 469, 476, 477–8, 490–500, 543, 571
- Bayesian decision theory 400–401, 456, 457, 544, 551–2, 566, 569–71, 589
- behaviour, health-related (causal effects) 36–44
- behavioural impact (performance) 355–6
- behavioural theory of weight 74–5
- behaviours, health 10–11
 - young people 60–67
- Belgium
 - health insurance 112
 - hospital competition 226
 - Panel Study 21–2
- Belize, GATS commitments 167
- bequests 319, 322, 323
- Beveridge health care systems 219, 221
- bilateral monopoly 231, 235, 237
- Birch, S. 419, 507, 513, 521, 528–36, 592, 593
- Bishai, D.M. 46–57
- Bismarck health care systems 219, 220, 221, 226
- Bleichrodt, H. 371–80, 383, 397, 406, 411, 426, 437
- Blinder-Oaxaca decomposition 179–81, 183, 184, 186–7
- body mass index 64, 70–71, 73–4, 78
- Bolivia
 - GATS commitments 167
 - unofficial payments 158, 167
- bonuses 126, 225, 274, 277, 298–304, 346
- Botswana, GATS commitments 167
- Bound, J. 24, 25, 26, 29, 30, 31, 39
- Box-Cox models 474, 475, 476, 478–9
- Bradford, W.D. 329–36, 363
- brain drain 170, 171
- Brazier, J.E. 372, 379, 383, 385, 387, 389, 395–403, 437
- Brazil 56
- breast cancer 43–4
 - QALY outcome 490–91, 498–9
- Breyer, F. 108, 123–31
- Briggs, A. 524, 539–48, 551, 565, 572
- Brunei Darussalam, GATS commitments 167
- Bulgaria
 - GATS commitments 167
 - unofficial payments 154–5, 167
- Burgess, J.F., Jr. 344, 359–65
- Burgess, L. 437, 439, 440, 447–57
- Burundi, GATS commitments 167–8
- Cambodia
 - contracting-out 252, 254, 256
 - unofficial payments 155, 160
- Canada 219
 - bargaining in health care 235
 - child mortality 51

- cigarette taxes 64
- cost-effectiveness analysis 530, 534
- drug-related crime 81, 83
- drug plan for seniors 115
- GATS commitments 168
- health services trade 168, 171
- NPHS 27
- OHIP 27
- older workers 27, 29
- patient cost sharing 118
- payment rates 275, 276
- PBMA 577, 580
- Pharmacare 118, 119
- pharmaceutical evaluation 443, 534, 586, 587, 590, 591
- priority setting 576, 577, 580
- public drug plan 114, 118, 119
- public health expenditure 219
- quality assessment 386–7, 390–91
- SLID 18
- taxing health benefits 114
- temporary movement of providers 171
- cancer 76, 522
 - cervical 505
 - EuroWill project 431
 - mortality 7, 8, 9
 - QALY model 373, 481
 - screening 195, 505, 590
 - testicular 373
 - see also* breast cancer
- capability approach (in health economics) 415–23
 - definition 415–17
 - implications 422–3
 - OCAP 420–21
 - role of health in 417–18
 - role in health economics 419–20
 - use of 420–22
- capitation system 275, 290, 292, 295
 - contracts and incentives 240–47
 - decision-making 285
 - effect on quality/quantity of services 284–5
 - future research 286–7
 - GPS and 280–87
 - hospitalization and 282, 285–6
 - incentives and 280–87, 362
 - mental health and 298
 - need-based 284
 - referral rate 285–6
 - as revenue system component 282–4
 - risk adjustment *see* risk adjustment
 - salary and 273–4, 276–7, 278, 281
 - studies 284–6
- cardiovascular disease
 - advertising and 332, 335
 - cost-effectiveness analysis 505, 513, 519–20, 524–5
 - economic instability and 5, 7, 8, 9
 - EPIC trial 591
- care homes *see* nursing home quality
 - of care
- caregivers (informal care) 323–5
- Caribbean
 - alcohol/tobacco use 516, 517
 - temporary movement of providers 171
- cataract operations 259, 261, 263, 431
- CD4 cell counts 505, 506, 511, 513
- Celebrex 335
- censoring 466–9
- Central and Eastern Europe 226
- cereals (plant breeding programmes) 54
- cervical cancer 195, 505
- Chalkley, M. 222, 231, 240–47, 250, 286, 289, 347
- childbirth 40, 275
- children 254, 256, 395, 408, 409
 - Asia 203, 204–5, 207
 - developing countries 46–57
 - HAZ scores 181, 184–5, 186, 187–8
 - mortality 5, 8, 9–10, 46, 48, 49–51, 56, 57, 182, 203–5, 213, 251, 255, 417, 516
 - nutrition 16, 46, 53–4, 57, 181, 184, 522
 - poverty 47–8, 49
 - see also* young people
- Chile
 - child mortality 51
 - health services trade 169
- China
 - cross-border supply of services 168
 - equity in health care 204, 206
 - GATS commitments 167
 - health care financing 210, 213
 - health care utilization 206
 - health services trade 167
 - legal drinking age 81–2
 - life expectancy 48
 - poverty and health expenditure 210–11
 - smoking 63
 - unofficial payments 155
- Chinese Taipei, GATS commitments 167
- Chisholm, D. 515–26
- Chlamydia screening test 444
- choice
 - behaviour, understanding 448–9
 - models 449–51
- choice experiments *see* discrete choice
 - experiments (design of); discrete
 - choice experiments (in health economics)
- choice sets/tasks 437–41

- cholesterol 299, 331, 333–5, 520–21, 539, 545–6, 547, 589
- chronic illness 16, 115, 140, 284, 293
 - advertising and 331
 - capability approach 418, 422
 - distributional judgements 408–9, 410
 - health utility measurement 371–6
 - mental health and 300, 301
 - older workers 27, 30
- Claxton, K. 516, 524, 547, 550–61, 569, 591
- clinical trials 589–92
 - see also* cost-effectiveness analysis and clinical trials (statistical methods)
- co-payments 127–8, 160, 212, 235, 264, 275, 332, 335–6
- Coast, J. 172, 397, 415–22, 438, 439, 441
- cocaine 62, 82, 83
- Colombia 11
 - unofficial payments 158
- Columbia, child mortality 51
- Commonwealth of Independent States 226
- communicable diseases 49, 198, 199
- community-based approach 429
- community care 318, 321, 429, 430, 431
- community support, loss of 12
- compensation 272–8, 285, 299, 303
- competing choice problem 505–12
- competition 275–6, 347
 - health plan choice 134–42
 - hospital 219–28
 - market (nursing homes) 309
 - waiting times 260, 261–2, 263
- CON (certificate of need) 309, 311, 312, 313
- conditional cash transfers 55–6
- Congo RP, GATS commitments 167
- consumers 60, 159
 - advertising direct to 329–36
- consumption 15
 - of health care (equity) 192–201
 - of health services (abroad) 166, 169
- contingent valuation (in health care) 425–36, 437
 - ability to pay 426, 427, 428, 432
 - clinical dilemmas 427–9
 - decision-maker's dilemmas 427–32
 - health authority dilemmas 429–31
 - national dilemmas 430, 432
 - willingness to pay 425–32, 435–6
- Contoyannis, P. 15–22, 118, 189
- contra-indications 329, 330
- contracting-out health service provision 250–57
 - accountability 257
 - contract evaluation 253–4
 - external funding 256
 - future research 257
 - globalization 257
 - government subsidies 251
 - hidden information 250, 255
 - impact on health system 257
 - information-poor settings 250–57
 - international funding agencies 250
 - motivation for 251–2
 - New Public Management 251
 - performance-based 256
 - policy implications 256–7
 - recent evaluations (examples) 254–6
 - resource-poor settings 250–57
 - resource allocation 251
 - services suitable for 251–2, 254–5
- contracts, information and incentives in health care 240–47
 - capitation *see* capitation system
 - costs of health care 242–3, 244
 - dumping 244
 - fees-for-service 273, 274–7, 278, 281, 285–6, 290, 302, 303
 - fixed prices 245–6, 247
 - health care reform 245–7
 - hidden information 241–5, 247, 250
 - moral hazard 241, 242–5
 - rent-seeking behaviour 246
 - salary system 273–4, 276–7, 278
 - services/treatment (categories) 247
- Cookson, R. 22, 193, 219–28, 246, 407, 411, 415, 420, 535, 536
- Copas tests 478
- corporatism 227
- corruption 154, 157–8, 160, 161
- cost-benefit analysis 415, 429, 438, 443
- cost-effectiveness acceptability curve (CEAC) 551–2, 570, 572
- cost-effectiveness analysis, future costs in 481–8
 - empirical studies 484–7
 - ethical and policy concerns 487–8
 - historical background 481–2
 - life expectancy 488
 - lifetime decision-making models 482–3
 - methods 484–6
 - QALY 481, 482, 485–7
 - theoretical basis 481–3
- cost-effectiveness analysis, generalized
 - alcohol use 516–20, 524–5
 - challenges 515–16
 - DALYs 516–20, 521, 523, 524, 525
 - IMC-CEA 515
 - policy uses 525–6
 - practice of 522–4
 - principles of 516–22

- QALYs 516, 523
 risk factors 524–5
 cost-effectiveness analysis, incremental
 (decision rules) 505–14
 budget constraint 507–8
 cardiovascular disease 505, 513
 cervical cancer example 505
 ‘competing choice’ problem 505–7, 509–11,
 512, 513
 framework extensions 512–14
 health improvement, maximising 507–8,
 510–11
 HIV example 505, 506–7, 509–11, 512–13
 indivisibilities 512–13
 interdependence between programmes 512
 multiple resource constraints 513–14
 programme alternatives 505–7, 509–11
 QALY 506–8, 509–11, 513
 ‘shopping spree’ problem 507–8, 510–11,
 512, 513
 cost-effectiveness analysis and clinical trials
 (statistical methods) 539–48
 applications 544–6
 average cost-effective ratios 541–2
 covariate adjusted CEA 542–3
 extensions 544–6
 Heart Protection Study 545, 547
 ICER statistic 539–40, 543, 546
 net-benefit regression 542–4, 546, 547
 net-benefit statistic 540–2
 QALY 544, 545
 standard approach to stochastic 539–42
 sub-groups 543, 545–6, 547
 cost-effectiveness ratio (CER) 524, 564, 573,
 592
 incremental (ICER) 525, 530–36, 539–40,
 543, 546, 572
 cost-effectiveness thresholds 508, 509, 551, 552,
 555, 592–3
 cost-utility analysis *see* health
 utility measurement
 Costa Rica
 child mortality 49
 contracting-out 256
 GATS commitments 167
 costs
 administrative 127, 225
 analysis 464–70
 collection 463–4
 data (skewed) 464, 473–9
 of dying 130
 future *see* cost-effectiveness analysis, future
 costs in
 health care 242–3, 244
 irrecoverable 559–60
 sharing 118–19, 298, 301, 303, 336
 transaction 257, 304, 341, 583
 zero 464, 482
 costs for economic evaluation, estimating
 463–70
 censoring 466–9
 cost analysis 464–70
 cost collection 463–4
 dependent on multiple measures 470
 generalized equation 470
 missing data 464–6, 470
 skewed cost data 464
 costs and expenditures, skewed data on 473–9
 alternative estimation approaches 474–8
 Box-Cox models 474, 475, 476, 478–9
 conditional density estimation 477–8
 generalized linear models 474, 475–7, 478–9
 OLS model 473, 474, 476, 478
 retransformation problem 474
 strengths and weaknesses 478
 counselling (drug abuse) 85
 Cox-2 inhibitors 335
 coxibs 117
 cream-skimming 170, 281, 352, 355–6
 crime 65
 illicit drug use and 81–8
 Croatia, GATS commitments 167
 crop breeding programme 54
 crowding out 227–8
 Cuba, health services trade 169
 Culyer, A.J. 419
 Currie, G. 246, 429, 437–44
 Cutler, D.M. 16, 17, 46, 48, 49, 55, 73, 74–5,
 77, 104, 110, 139–40, 236, 290, 293, 308,
 312
 Cyprus, hospital competition 226
 cystic fibrosis screening 436
 Czech Republic 87
 GATS commitments 167

 DALYs 54, 411, 523, 525
 data analysis 363, 364, 441–2
 Dawson, D. 219–28, 246
 DCA *see* advertising, direct to consumer
 (DCA)
 death threshold 18
 Deb, P. 144–52, 192
 decision-makers
 dilemmas (contingent valuation) 427–32
 needs of 531–4
 priority setting methods 576–83
 problems (economic basis) 528–30, 535
 risk from perspective of 564–72
 decision-making 419
 capitation and 285

- CEAC 551–2, 570, 572
- central level 586–7
- clinical studies 589–90
- cost-effectiveness thresholds 592–3
- criteria (priority setting) 577–8
- delegated 341
- evidence of use of economic evaluation 586–8
- EVPI 553–7
- lifetime (models) 482–3
- methodological issues 588–90
- QALY 590, 592–3
- decision-making (use of economic evaluation) 586–93
 - central level 586–7
 - clinical studies 589–90
 - cost-effectiveness thresholds 592–3
 - data adjustment 591–2
 - equity assumptions 590
 - evidence of use 586–8
 - indirect clinical comparisons 588–9
 - local level 586, 587–8
 - methodological issues 588–90
 - practical issues 590–93
 - priority setting 590–91
 - QALY 590, 592–3
- decision-making with uncertainty (value of information) 550–61
 - CEAC 551–2
 - efficient research design 557–9
 - ENBS 558–9
 - evidence acquisition 553–60
 - evidence forgone 560
 - EVPI 553–7, 559, 591
 - EVSI 558–9
 - implementation strategies 560
 - inference (irrelevance of) 552–3
 - irrecoverable costs 559–60
 - requirements of 550–51
 - technology adoption 551–3
- decision rules in economic evaluation 528–36
 - alternative approach 535
 - cost-effectiveness analysis 530
 - economic basis 528–30
 - ICER (consequences) 534–5
 - needs of decision-makers 531–3
 - see also* cost-effectiveness analysis, incremental (decision rules)
- demand-side effects 308–9, 321
- dementia 324, 388
- Denmark
 - capitation system 281
 - child mortality 50
 - EuroWill project 431
 - hospital competition 226
 - physician payments 281
 - public health expenditure 219
 - willingness to pay 431
- dental health 110, 130
- depression 32, 385–6, 390
 - advertising and 331, 334
 - informal care 324, 325
 - postnatal 408
 - quality of mental health 299, 300, 302, 303
 - Robert Wood Johnson Foundation 300, 302
- developing countries 522
 - child mortality 46, 49, 50–51
 - e-health 168
 - FDI 170
 - health care worker shortage 53
 - health services trade 168, 170
 - public health interventions for children 46–57
 - water quality 52, 54–5
 - see also individual countries*
- diabetes 119, 283, 293, 299, 330, 484, 486, 589
 - type 2 76, 278, 383
- Diagnosis Related Groups (DRGs) 222–3, 226, 227, 245, 247, 364
- dialysis 486
- diarrhoea 46, 53, 179, 206
- diet 10, 307, 486
 - calorie consumption 71, 72, 77
 - see also* food; nutrition; obesity
- digestive system 199
- diphtheria 54
- direct to consumer advertising (DCA) *see* advertising, direct to consumer (DCA)
- direct payments 209, 210–11, 213
- direct treatment costs 463
- disability 28, 60, 309, 396, 408–9, 419, 418
 - DALY 54, 411, 523, 525
 - informal care 321, 324–5
 - insurance 24, 27, 29, 30, 31
- discrete choice experiments (design of) 447–57
 - binary response experiments 451–2
 - choice models 449–51
 - force choice experiments 452–3
 - generic choice experiments 452–5
 - random utility theory 449–51
 - resolution 3 design 451, 453, 455–6
 - understanding choice behaviour 448–9
 - unresolved issues 456–7
 - with constant options 455–6
- discrete choice experiments (in health economics) 138, 344, 397–8, 421, 431–2, 437–44, 581
 - attribute identification 438–9
 - choice sets/tasks 437–8
 - choice sets construction 439–41

- concept 437–8
- data analysis/interpretation 441–2
- feasibility of 449
- price as attribute 438–9
- QALY model 437, 443
- stages of 438–42
- survey design 441
- time as attribute 439
- using 442–3
- validity of 443–4
- willingness to pay 438–9, 441, 444
- Disease Control Priorities project 52
- disinvestment 577, 578–9, 580
- distance function 359, 364
- distributional judgements *see* economic evaluation (distributional judgements)
- District Health Authorities 254, 282
- diuretics 116
- divisibility assumption 512–13, 531–2
- Dolan, P. 376, 379, 386, 396, 397–9, 400, 406, 409, 411–12
- Dominican Republic, GATS commitments 167
- Donaldson, C. 246, 419, 425–32, 435–7, 533, 535–6, 576–9, 581–2, 587, 593
- donor agencies 53, 250, 252
- Dowd, B.E. 97, 110, 111, 134–43, 220, 246
- Dranove, D. 40, 222–3, 224, 275, 356, 463
- drugs/drug use 36, 252, 275, 298–9, 301, 302
 - amphetamines 83
 - background on illicit 81–2
 - cocaine 62, 82, 83
 - crime and illicit use 81–8
 - decriminalization 85, 86–7
 - demand and supply 85–6
 - dependency 82, 87
 - employment and 82
 - harm-reduction 85, 86–7, 88
 - heroin 82, 85, 86
 - inhalants 82
 - labelling 396
 - legalities of 81–2
 - legalization 85, 86–7
 - marijuana 64, 65, 81, 82, 86, 87
 - needle exchange 87
 - preventive programmes 85–6
 - prior authorization 117
 - reducing costs of illicit use and crime 84–7
 - research challenges 87–8
 - sexual behaviour and 40
 - smuggling/trafficking 83, 86
 - treatment for 83, 85, 87
 - see also* prescription drugs
- Drummond, M.F. 383, 389, 463–4, 515, 535, 541, 576, 586–93
- dual practice 155, 159, 160
- duality theory 359
- dumping 223, 224, 304
- dynamics of health 15–22
- dyslipidemia 76
- e-health 168
- ear problems 199, 384, 385, 386, 396
- Eastern Europe
 - temporary movement of providers 171
 - see also individual countries*
- ECHP (European Community Household Panel) 19, 22, 148
- Econlit 280
- economic evaluation
 - decision-makers and *see* decision-making (use of economic evaluation)
 - decision rules *see* decision rules in economic evaluation
 - estimating costs *see* costs for economic evaluation, estimating
 - in health care (mean-based) *see* health care evaluation (mean-based)
 - see also* preference-based measures of health; health-related quality of life (HRQL) assessment
- economic evaluation (distributional judgements) 406–13
 - ability to pay 407
 - aggregation-related counter-arguments 407, 410
 - equity counter-argument 408–10
 - fair innings argument 407, 409, 410
 - health variance 407, 408–9
 - QALY (Principle Q challenged) 407–10
 - QALY (Principle Q supported) 410–12
 - QALY (value of) 406, 407–10
 - QALY maximization 406, 412–13
 - social perspective 407, 409–10, 411
 - social preference 411, 412
- economic growth 11–12, 49
- economic models (informal care) 319–20
- economic theories (physician's economic behaviour) 271–4
- economies of scale 222, 360, 361
- economies of scope 360, 361
- Ecuador 53
 - GATS commitments 167
- education
 - levels 16, 17, 198, 200, 263, 321
 - training and 168, 169, 170
- efficiency
 - allocative 251, 360, 515
 - based methods (productivity analysis) 360–62, 363
 - contracting out and 251, 253, 254

- cost estimating and 467, 468
 - hospital competition and 220–21, 227
 - social health insurance 123–4
 - technical 251, 360, 528–9
- elderly *see* ageing
- emergency services 222
- emphysema 572
- employment 7, 16, 65
 - health insurance and 108
 - health service utilization 200–201
 - illicit drug use and 82
 - injury risk 11
 - labour supply 24, 26, 28, 29, 30
 - older workers 24–32, 290
 - sedentary 73
 - working conditions/hours 11
 - see also* work; workforce
- endocrine and metabolic disorders 199
- England 578, 586
 - equity in health care consumption 198–201
 - health service utilization 198–9
 - Health Survey for (HSE) 198
 - hospital competition 219, 220, 224–6
 - Labour government 263
 - performance measurement 352–3, 356
 - waiting times/lists 259, 261, 262–3
 - see also* UK
- Ensor, T. 154–61, 213
- entry regulations 221, 222
- envelope theorem 363, 364, 485
- environment, physical 7, 16, 47
- EPIC trial 591
- epidemiological data 52, 66, 521, 522–3, 525, 589
- equal treatment for equal needs 205
- Equitap study 203–4, 206, 207–8, 209–11
- equity 203, 224, 227, 406, 590
 - Asian health care system *see* Asia (equity in health/health care)
 - decomposition of inequalities 179–89
 - horizontal 192–3, 194, 196
 - public health intervention 47–8
 - vertical 192–3, 194, 197, 198, 201, 209
- equity in consumption of health care
 - economic studies of 192–201
 - England 198–201
 - horizontal/vertical inequity 197–8
 - problems in analyses of inequity 195–8
 - welfare maximization and need 192–5
- erectile dysfunction 118
- Estonia, GATS commitments 167
- ethics 22, 155, 169, 416, 560, 582–3
 - cost-effectiveness analysis 487–8, 512–13
- ethnicity 8, 82, 196, 200, 201
- Ettner, S.L. 10, 276, 297–305, 321
- Europe
 - Asia (comparisons) 203–6, 209, 211–12
 - bargaining in health care 233–4, 237
 - Beveridge system 219, 221
 - Bismarck system 219, 220, 221, 226
 - child mortality 50–51
 - dual practice 155
 - GP and specialist use 205–6
 - health care financing 209
 - health insurance 144
 - health plans 135
 - incentive reimbursement 226
 - informal care 318, 321, 323–4
 - medical costs 484
 - retirement 24
 - see also individual countries*
- European Union 587
 - ECHP 19, 148
 - ECHP-UDB 22
 - Equitap study 203–4, 206, 207–8, 209–11
 - EuroWill project 430
 - GATS commitments 167–8
 - macroeconomic effect on mortality 9
 - social health insurance 131
 - see also individual countries*
- EuroQol (EQ-5D) 385–6, 388–90, 396–7, 399, 421
- EuroWill project 430
- Evans, D.B. 515–26
- exercise 12, 36, 60, 64, 72, 78, 486
 - physical inactivity 10, 73
 - see also* diet; obesity; weight
- exit 221, 222, 348
- expenditure
 - effect on informal care 321–2
 - skewed data 473–9
- extra-welfarism 419, 420, 422, 487
- extrapolation approach 589–90
- eye problems 199, 354, 385, 386, 396
- family as carers 308, 309, 318–25
- famine 416
- fee-for-service systems
 - capitation and 281–2, 284, 285–6
 - physician as agent 273, 274–7, 278
 - risk adjustment and 290, 297, 302–3
- feedback mechanisms 351
- feeding tubes (in nursing homes) 312
- Feeny, D. 383–92, 395, 396, 398–9, 437
- Feldman, R. 97, 110–11, 134–42, 220, 246
- Fenwick, E. 516, 524, 550–61, 591, 570, 572
- Fieller's theorem 540
- financing
 - Asian health care 209, 212–13

- nursing homes 307–8
- public funded health care 219–28
- finite-sample properties 39, 40
- Finland
 - alcohol-related mortality 10
 - child mortality 50
 - GATS commitments 167
 - hospital competition 220
 - obesity 10
- fixed prices 222–3, 244, 245–6, 247
- food 307, 416
 - addiction 74, 75
 - fortification 54, 525
 - pricing 64, 72–4
- foreign direct investment 166, 170
- foreign travel 169, 172
- formal care 319, 320–22
 - see also* GPs; hospitalization; hospitals; primary care
- France
 - capability approach 417
 - child mortality 50
 - EuroWill project 431
 - hospital competition 226, 227
 - legal drinking age 81–2
 - macroeconomic effect on mortality 7, 9
 - physician-induced demand 275–6
 - public health expenditure 219
- free-rider problem 47, 123, 320
- Gafni, A. 272, 426, 429, 507, 513, 521, 528–36, 592, 593
- gallbladder disease 76
- Gambia, GATS commitments 167–8
- game theory 319–20
- gaming 284, 345–6, 351, 352, 354
- Gamma model 478
- GATS (General Agreement on Trade in Services) 165, 166, 171, 172
- GATT (General Agreement on Tariffs and Trade) 165
- gender 18–19, 49, 82, 290, 308–9
 - distributional judgements 407, 411
 - informal care 322, 324, 325
 - obesity and 70–71, 78
- generic products 118, 329, 335
- genitourinary system 199
- genomics 172–3, 570
- Geoffard, P.-Y. 103–12, 116, 128, 136, 290
- Georgia, GATS commitments 167
- Gerard, K. 246, 437–44, 447
- Gerdtham, U.-G. 5, 6, 7–8, 10, 125, 186
- Germany
 - capability approach 417
 - child mortality 10, 50
 - health plans 135, 290, 295
 - hospital competition 226, 227
 - income levels 17
 - macroeconomic effect on mortality 7, 8, 10
 - older workers 30
 - public health expenditure 219
 - social health insurance 125, 127
 - Socioeconomic Panel (GSOEP) 17, 146
 - unemployment 30
- Gertler, P.J. 56, 235, 310–12, 361, 362
- GHQ (General Health Questionnaire) 21, 198, 199
- Gini indices 20–21, 186
- Glazer, J. 112, 129, 289–95, 303
- globalization
 - consumption abroad 166, 169
 - contracting-out services 257
 - cross-border supply 166, 168–9
 - current challenges 171–2
 - e-health 168
 - education/training (web-based) 168
 - foreign direct investment 166, 170
 - future prospects 171–2
 - GATS commitments 165–6, 171, 172
 - global health governance 171
 - health economics and 172–3
 - health services trade 164–73
 - temporary movement of providers 166, 170–71
 - waiting lists and 169, 172
- Gold, M. 100, 398, 463–4, 481, 531, 534
- gonorrhoea 66–7
- government policies 62–3, 125, 216, 355
 - advertising and 329, 330, 331
 - hospital competition and 226–8
 - nursing homes 307–8, 309, 310
 - obesity and 76–8
 - subsidies 251, 252, 254
 - see also individual countries*
- GPs (general practitioners) 119, 205, 356
 - capitation 280–87
 - contracting-out 255, 257
 - equity in consumption 196, 198–201
 - fundholders 118, 225, 236, 260, 262, 277–8, 282
- Grabowski, D.C. 276, 307–14, 318–25
- Gravelle, H. 5, 192–201, 225, 261, 262, 264, 282, 284
- Greece 219
 - unofficial payments 157
- Grootendorst, P. 40, 114–20
- Grossman, M. 15–16, 17, 18, 22, 25, 60, 62, 64, 77
- Guyana, GATS commitments 167

- haemoglobin testing 283
- haemophilus 54
- Haiti, contracting-out 255–6
- hallucinogens 82
- Handbook of Health Economics* 307
- Harvard death spiral 110
- hay fever 330
- health
 - definitions 396, 401–2
 - demand for 15–16
 - dynamics of 15–22
 - equity in *see* equity
 - inequality 20–22, 179–89
 - measurement of 26–31
 - persistence in (reasons) 16–18
 - profiles 376–7
 - redistribution of 125–6
 - role (in capability approach) 417–18
 - status 48, 49, 52, 204–5
 - work and *see* work
 - workers 53, 171, 251–2, 307, 310–11
- health-related quality of life (HRQL)
 - assessment 383–92, 409, 411
 - applications 389–90
 - approaches 383–6
 - construct validity 388, 390
 - direct approach 383–4
 - EuroQol 385–6, 388, 389–90
 - future directions 390–92
 - HUI 385, 386–8, 389–91
 - life expectancy and 390, 391
 - multi-attribute utility approach 384–90
 - psychometric measures 383, 384–6
 - Quality of Well Being scale 385, 387, 388, 389
 - SF-6D scale 385, 387, 388–90
 - SG 383–4, 385–7, 390, 397
 - Short-Form 36 204, 383, 385, 388, 390
 - TTO 383–4, 385–6, 390, 397, 399
 - VAS 383–4, 385, 386, 390, 397, 399
 - see also* economic evaluation, distributional judgements; preference-based measures of health
- health capital model 11, 124
- health care evaluation
 - capability approach *see* capability approach (in health economics)
 - contingent valuation *see* contingent valuation (in health care)
- health care evaluation, mean-based 563, 73
 - CEAC 570, 572
 - CER 564, 572
 - current criteria 572–3
 - decision-maker's perspective 564–72
 - heterogeneity 564–72
 - net health benefit 572
 - net monetary benefit 572
 - quantile treatment effects 573
 - risk factors/uncertainty 564–72
 - welfare assessment 572–3
- health care organizations *see* performance of health care organizations (measuring)
- health care professionals, motivation of 247
- health care systems, performance of *see* performance measures in health care systems
- health care use 254
 - empirical models 144–52
 - endogenous covariates 149–50
 - equity in 205–7
 - exogenous covariates 145–8
 - hurdle (two-part) models 145–6, 147, 148
 - latent class models 147–8
 - parameters 151
 - Poisson regression model 145, 146, 147, 476, 478
 - zero-inflated models 146–7
- health economics
 - capability approach *see main entry*
 - causal effects 40–44
 - discrete choice experiments *see main entries*
 - globalization and 172–3
- health insurance 24, 30, 77, 209, 271, 290, 297, 302, 355, 449
 - adverse selection 103, 114–15, 139, 141, 144
 - certainty, demand for 94–6
 - coverage 104–5
 - demand, price elasticity 107–8
 - drug plan remuneration 119–20
 - e-health and 168
 - empirical issues 108–11
 - employment linked 108
 - FDI 166, 170
 - financial liberalisation 165–6
 - first best 105–6
 - gains from 114
 - health plans *see* health plans
 - incentive/selection effects 103–12
 - income transfers 98–100, 105
 - moral hazard 93, 96–101, 103–4, 108, 109, 114–15, 116–19, 125, 128–9
 - mortality and 110–11, 119
 - optimal taxation 123–4
 - patient cost sharing 118–19
 - pharmaceutical innovation 119–20
 - physicians as patient's agent *see* physician as patient's agent
 - policy implications 111–12
 - pre-payment schemes 117

- prescription drugs and reimbursement 114–20
- RAND Experiment 97, 109–10, 111
- reference pricing 118, 119
- regulation of 108
- reimbursement 107, 114–20
- risk prediction 105–6, 123–4, 126–7, 129–31
- second best 106–8
- social *see* social health insurance
- solidarity 124
- technological changes in medicine 131
- theory 104–8
- utility concept 94–6, 99, 100, 105–6
- value of 93–101
- welfare gain 96, 98–9, 100, 101
- welfare loss 96–8, 99, 101, 103–4, 108, 116
- health plans 147, 290, 291
 - adverse selection 139, 141
 - basic choice model 139–41
 - choice literature 134–6
 - consumer characteristics 136–7, 140–41
 - empirical innovation 139–41
 - individual level data 136–7
 - health insurance market 141
 - market for services 141
 - market share data 138–9
 - mental health 298, 299, 304
 - mergers 135
 - physician loyalty 134
 - plan switching 135–6, 140–41
 - profit maximization 294–5
 - quality choices 292–4, 298, 355
 - risk adjustment *see main entry*
 - risk segmentation 139
 - service-level selection 292–3, 294–5
 - study methods 136–9
 - value-based purchasing 298–9
- Health Resource Group (HRG) 245, 247
- health services
 - priority setting *see main entry*
 - trade *see* globalization
- health utility measurement 371–80
 - characterizations under expected utility 372–3, 377–8
 - chronic health states 371–6
 - generic utility model 374, 375
 - life duration trade off 375–6, 377
 - non-chronic health states 376–9
 - non-expected utility 374–5, 379
 - prospect theory 374–5
 - QALY model 371–5, 377–8, 379, 380
 - zero condition 372–3, 374, 375
- Health Utility Index 385, 386–91, 396
- heart disease 5, 7, 8, 10, 11, 76, 278, 523, 589
 - EuroWill project 431
 - medical costs 481, 484, 486
 - myocardial infarction 9, 225, 226, 262, 591
 - performance monitoring 352, 354, 355
 - risk reduction 425
 - treatment decision rules 529–30
- Heart Protection Study 545, 547
- Heckman, J.J. 41, 42, 43, 109, 492–5, 496, 497–8, 563, 571, 573
- height
 - as health indicator 48–9, 52
 - for-age z scores (HAZ) 181, 184–5, 186
- helicopter ambulance 429, 431
- hemophilus 54
- Herfindahl-Hirschman Index of concentration 224
- heroin 82, 86
- Hicks, J.R. 362, 428
 - see also* Kaldor-Hicks theory
- hidden biases 493, 494, 496–8
- hip 429, 444
 - fracture prevention 486
 - operations (EuroWill project) 431
 - replacement 225, 259, 261, 263
 - treatment decision rules 529–30
- HIV/AIDS 48, 251–2, 486, 505, 515
 - QALY 486, 506–7, 509–11, 513
- Holland *see* Netherlands
- home health care 309, 320–21
- homicide 5, 7, 8, 9, 60
- Hong Kong
 - equity in health care 203, 205, 206, 207, 208, 209, 214
 - government social spending 207, 208–9
 - health care financing 209, 210, 212
 - health care utilization 205, 206
 - poverty and health expenditure 211
 - tax system 212
- hormone replacement therapy 486
- hospice care 309
- hospital competition and patient choice (publicly funded health care) 219–28
 - Beveridge style systems 219, 221
 - Bismarck style systems 219, 220–21, 226
 - corporatism 227
 - cross-border movement 226
 - definitions/objectives 220–21
 - DRGs 222, 223, 226, 227
 - economic theory 220–24
 - economies of scale 222
 - emergency services 222
 - entry/exit regulations 221, 222
 - geographical equity of access 224
 - imperfect 222–3
 - league tables 221
 - ‘medical arms race’ 222

- monopolistic 222–3
- non-price 223
- political constraints 226–8
- price regulation 221–2
- public funding limits 222–3, 226–7
- publicly funded systems 224–6
- quality and waiting times 223–4, 225
- regulatory environment 221–2
- reimbursement 221, 226
- rent-seeking 227
- selective contracting 221
- supply-side impediments 221, 222
- worker satisfaction 227
- hospitalization 119, 206, 557
 - capitation and 282
 - nursing homes and 311, 312, 314
 - physician as patient's agent 274, 277
- hospitals
 - catchment area 260, 261, 262
 - distance to 261
 - length of stay 282
 - patient choice 261
 - productivity measurement 360–61, 364
 - referral rates 260, 285–6
 - star rating system 353–4
 - waiting lists *see* waiting lists
- Huckfeldt, P.J. 62, 70–78
- Hungary
 - GATS commitments 167
 - unofficial payments 155, 157
- hurdle models 145–6, 147, 148, 150
- hygiene 52, 522
- hypercholesterolemia 484
- hyperglycaemic emergencies 283
- hyperlipidemia 505
- hypertension 76, 116, 119, 481, 486, 505
 - willingness to pay 435, 513, 522
- IMC-CEA 515
- IMCI 53
- immunization 254–5, 256
 - developing countries 48, 52–5, 56, 57
 - influenza vaccinations 481–2, 486
- incentives 351, 356
 - contracting out and 251, 255–6
 - contracts and *see main entry*
 - design/evaluation 302–4
 - financial (productivity) 362
 - primary care 280–87, 362
 - 'real world' applications 298–301
 - risk adjustment 289, 293–4, 295
 - role (mental health care) 297–305
 - and selection effects (in health insurance) 103–12
 - see also* rewards
- income levels 6, 11, 16, 18, 115, 418
 - contingent valuation and 432
 - distributional judgements and 407–8
 - health service utilization and 196, 200, 201
 - income mobility 20–22
 - weight and 73
- India 53, 56
 - child health and maternity services 207
 - child mortality 48, 49, 205
 - contracting-out 252
 - e-health 168
 - equity in health care 204–7, 209
 - FDI 170
 - GATS commitments 167
 - government social spending 207, 209
 - health care financing 210, 212
 - health care utilization 206
 - health inequalities 204
 - health services trade 167, 168–71
 - poverty and health expenditure 211
 - temporary movement of providers 171
- Indonesia 53
 - child health and maternity services 207
 - child mortality 205
 - equity in health care 205, 206, 207–8
 - government social spending 207, 208
 - health care financing 210, 212
 - health care utilization 206
 - poverty and health expenditure 210–11
 - tax and direct payments 213
- induced demand 274–5, 276
- inequalities in health care
 - concentration index 183–6
 - decomposition of 179–89
 - difference in mean health 179–83
 - distribution changes 186–9
 - Oaxaca-type decomposition 179, 180–81, 183, 184, 186–7
- inequity 192, 195–8, 201
- infants *see* children
- infectious diseases 49, 198, 199
- influenza 7, 9, 54, 551, 555, 557
 - vaccination 481–2, 486
- informal care 308, 309, 318–25
 - bargaining models 319–20
 - caregivers 318, 319–21, 322–5
 - demand-side effects 321
 - economic models 319–20
 - facts/trends 318–19
 - formal care and 319, 320–22
 - inter-vivos transfers 322–3
 - supply-side effects 320–21
- information
 - acquisition costs 115

- asymmetry 103–9, 123, 128, 220, 237, 240, 272, 311, 313–14, 341–2, 348
 EVPI 553–7, 559, 591
 hidden 104, 241–5, 247, 250, 255, 341
 impact/use (performance) 355–6
 imperfect 284, 341
 perfect 347, 553–7, 559, 591
 -poor settings 250–57
 value of 550–61
see also contracts, information and incentives in health care
- inter-vivos transfers 322–3
 internal market 225, 257
 international funding agencies 250
 investment 15
 FDI 166, 170
 priority setting 577, 578–9, 580
 ‘inexit’ theory 156
 Iran 86
 Ireland, EuroWill project 431
 iron deficiency 520, 521, 524, 525
 Islamic societies, child mortality 49
 Israel 219
 health plans 295
 Italy
 capitation in primary care 283
 child mortality 50
 hospital competition 219, 220
 informal care 318
 Iversen, T. 259–66, 275, 276, 280–87, 289, 298
- Jamaica, GATS commitments 167
 Japan
 child mortality 51
 equity in health care 203, 205, 209, 214
 GATS commitments 167–8
 health care financing 209, 210, 212
 health care utilization 203, 205
 informal care 318, 321–2
 poverty and health care expenditure 210
 public health expenditure 219
 social insurance system 212
 JCAHO (now Joint Commission) 299
 Johannesson, M. 5, 6, 373, 378, 426, 429, 435, 484, 485, 531, 590
 Jones, A.M. 15–22, 63, 109, 185, 186, 189, 192, 197, 477, 478
 Jordan, GATS commitments 167
 justification bias 25, 26, 29, 31
- Kakwani indices 157, 209, 210
 Kaldor-Hicks theory 428, 563, 564, 567, 569, 572
 Kaplan-Meier probability 467, 468
 Kazakhstan, unofficial payments 156, 157, 159
 Kenkel, D.S. 60–67, 152
 Kleit, A.N. 329–36
 knee replacement 259, 263, 390
 Korea
 equity in health care 203, 204, 205, 209, 214
 health care financing 209, 212
 health care utilization 205
 poverty and health expenditure 211
 social insurance system 212
 Kuwait
 GATS commitments 167
 health care quality 169
 health services trade 167, 169
 Kyrgyzstan
 equity in health care 207, 210
 GATS commitments 167
 government social spending 207
 health care financing 210, 212
 poverty and health expenditure 210
 social insurance system 212
 unofficial payments 154, 160
- labour market 76, 234
 informal care and 319, 323, 324
 status 24, 25, 27, 30
 labour supply 24, 26, 28–30, 323
 see also employment; workforce
 Lagrange multiplier 194
 Lakdawalla, D.N. 62, 70–78, 117, 234, 309
 Latin America 48, 55, 516–17, 587
 unofficial payments 155, 158
 see also individual countries
 Latvia, GATS commitments 167
 league tables 221, 348, 354, 524, 530–31
 leisure time 12, 25, 30, 319
 Lesotho
 contracting-out 252
 GATS commitments 167
 Libya 49
 life duration trade-off 375–6, 377
 life expectancy 48–9, 100, 390, 391, 409, 411, 417, 482, 488, 545
 lifetime decision-making model 482–3
 Lindeboom, M. 24–32, 307
 literacy rates 417
 Lithuania, GATS commitments 167
 liver disease 7, 8, 9, 412
 Lives Saved Tool (LIST) 52
 location-specific fixed effects 6–11
 Lorgelly, P. 415–22
 Louviere, J. 437, 439, 440, 441, 442, 443–4, 447–57
 low-income countries (unofficial payments) 154–61

- Luràs, H. 276, 280–87, 289, 298
 Luxembourg, hospital competition 226
- Macao, cross-border supply 168
 Macedonia, GATS commitments 167
 McFadden, D. 136, 261, 438, 441, 449–50
 McGuire, A. 240, 246, 463–70
 McGuire, T.G. 112, 129, 275, 281, 283, 289–95, 303, 347
 macroeconomic conditions 5–11
 Madagascar, contracting-out 252
 major vascular events (MVEs) 545–7
 malaria 46, 47, 515, 522
 Malawi
 capability approach 422
 contracting-out 252
 GATS commitments 167
 Malaysia
 equity in health care 203, 204, 205–7
 FDI 170
 GATS commitments 167
 government social spending 207
 health care utilization 205, 206
 health services trade 167, 170
 tax systems 212
 mammography 299
 managed care 134, 141, 221, 224, 231, 235, 299, 329
 Manning, W.G. 97, 100, 108, 109, 125, 128, 146, 246, 464, 469
 mapping 401
 marginal analysis 577, 578, 583
 marginal approach 41, 42, 427, 428, 430
 marijuana 64, 65, 81, 86, 87
 market
 characteristics 308–11, 313
 failure 103, 108, 112
 share data (health plans) 138–9
 Martinez-Giralt, X. 231–7, 285
 Mason, H. 246, 425–32, 435–7, 533
 mastectomy 490, 491, 498–9
 maternal employment 65
 maternal mortality 251
 measles 54
 Medicaid 93, 99, 586
 advertising (DCA) 336
 drug programme 117, 119
 financial incentives 299–300
 fixed prices 245
 health plans 141
 informal care and 321
 nursing home quality of care 307–13
 obesity and 76
 payment system 245, 307–8, 309–14
 risk adjustment 293, 295, 302
 ‘medical arms race’ 222
 medical care
 health behaviours and 10–11
 insurance *see* health insurance
 redistribution of 125
 medical home payment system 290
 medical research 172
 Medicare 93, 490–91, 498
 advertising (DCA) 336
 drug programme 115
 financial incentives 299–300
 health plans 134, 140–41
 hospital care 221, 222, 225
 informal care 320, 322
 Modernization Act (2003) 234
 nursing home quality of care 307–13
 obesity and 76
 payment system 222, 245, 275–6, 307–13
 risk adjustment 290, 291–2, 294–5, 474
 Medline 168, 280
 Meltzer, D. 74, 481–8, 524
 meningitis 54
 mental health 17–18, 522
 economic instability and 5, 10, 21
 financial incentives 298–305
 illicit drug use and 82, 84
 incentives (for quality improvement) 297–305
 inequalities 21
 patient choices 297
 patients’ abilities undermined 297
 pay-for-performance 298–301, 304
 psychosocial health 198, 201
 quality measures 297–8, 300–304
 risk adjustment 302, 303
 value-based purchasing 298–9
 mental states 416
 mergers, vertical 233
 methadone maintenance 85
 Mexico 11, 87
 child mortality 51
 GATS commitments 167
 health services trade 167, 169
 Progressa-Oportunidades 55–6
 micronutrients 54
 middle-income countries (unofficial payments) 154–61
 migration 12, 169, 171, 172
 Mills, A. 209, 250–57
 Mitton, C. 536, 576–83, 587
 Miyamoto, J.M. 372, 373, 374–5
 mobility, health inequalities and 20–22
 model building 580, 581
 modelling 157–9, 399–401, 402, 591–2
 Moldova, GATS commitments 167

- Mongolia, social insurance system 212–13
 monopolistic competition 222–3
 Monte Carlo model 40, 52, 551, 554, 589
 Mooney, G. 196, 272, 419, 536, 578
 moral hazard 347–8
 advertising and 330, 335
 health insurance 93, 96–8, 99, 100, 101, 103–4, 108, 109, 114–19, 125
 hidden information and 241, 242–5
 social health insurance 126, 128–9
 waiting times and 264
 morbidity 193, 195–8, 201, 309, 383, 390, 545
 morphine 82
 Morris, S. 56, 192–201
 mortality 18, 26, 299, 373
 adult 7–10, 308–9, 516
 Asia 203, 204–5
 child 5, 8, 9–10, 46, 48–51, 56–7, 182, 203, 204–5, 213, 251, 255, 417, 516
 decline 48, 49–51
 elderly people 308–9
 health insurance and 110–11, 119
 hospital competition and 225, 226
 league tables 354
 macroeconomic conditions and 5–11
 maternal 251
 performance measurement and 352, 354–5
 rates 347
 retirement age and 31, 32
 smoking 417–18
 spousal caregivers 324
 starvation 416
 waiting times and 262
 motivation 272, 281
 for contracting-out 251–2, 255
 extrinsic 228
 intrinsic 227, 228, 343, 347, 351, 356
 Mullahy, J. 146, 149, 152, 464, 474, 476–8, 493, 540, 550, 551, 563–73
 multi-attribute utility approach 383–92, 398, 399, 402, 419
 applications 389–90
 disease-specific 391
 estimation of 387–8
 functional forms 383, 384–6
 future direction 390–92
 properties of (comparisons) 388–90
 systems 386–8
 value of (ongoing debate) 391–2
 see also health-related quality of life (HRQL) assessment
 Multi Criteria Decision Analysis (MCDA) 579–81, 582
 musculoskeletal system 198, 199
 Nair, D. 46–57
 Nash bargaining model 62, 232–3, 235
 National Health Service 234, 236, 245, 263, 277, 283, 356, 534, 561, 578
 Act (1946) 93
 economic evaluation 586, 591, 593
 Health Technology Assessment 560, 586
 hospital competition 221, 225
 internal market 225
 mental health 300, 304
 social health insurance 123, 126
 National Institute for Clinical Excellence (NICE) 398, 403, 419, 430, 443, 530, 534, 536, 550, 552, 560–61, 586, 589–91, 592–3
 natural justice 409
 need 192–5, 196, 197–8, 426
 negotiation and bargaining in health care 231–7
 ‘any willing provider’ 233–4, 237
 future research 236–7
 group preferences 234–5
 models of 231–5
 Nash bargaining 232–3, 235
 outcomes (evidence) 235–6
 pharmaceutical products 235, 237
 public-private partnership 234–5, 237
 third-party payer decisions 233–7
 timing of 237
 neonatal deaths 8, 9, 10, 56
 neoplasms and benign growths 199
 Nepal
 child health and maternal services 207
 child mortality 205
 equity in health care 204, 205–7
 FDI 170
 health care financing 210, 212
 health care utilization 206
 health inequalities 204
 poverty and health expenditure 211
 tax and direct payments 213
 unofficial payments 155
 nervous system 199
 net-benefit statistic 540–42
 net health benefit (NHB) 541, 572
 net monetary benefit (NMB) 541–2, 572
 Netherlands 27–8
 capitation system 281, 285
 health expenditure 126
 health plans 135, 140, 290, 295
 hospital competition 220, 226
 informal care 318
 marijuana use 81
 Panel Study 21–2
 pharmaceutical evaluation 590

- priority setting 576
- social health insurance 126, 127
- 'New Public Management' 251
- New Zealand 587
 - advertising (DCA) 329
 - hospital competition 220
 - PBMA 577
 - priority setting 576, 577
 - temporary movement of providers 171
- Newhouse, J.P. 41, 108, 109, 110, 123, 125, 245, 246, 281, 293, 362–3, 365
- Nicaragua 56
- Nigeria 167
 - contracting-out 252
- NLSY 65, 73
- NOAA 427
- non-government organizations (NGOs) 250, 251, 252, 254–5, 256–7
- non-insurable loss 127–8
- Norton, E.C. 276, 307–14, 318–25
- Norway
 - capitation system 275, 276, 281, 284–6
 - child mortality 50
 - EuroWill project 430, 431
 - GATS commitments 167
 - helicopter ambulance 429, 431
 - hospital competition 226
 - outpatient programme 42
 - public health expenditure 219
 - social insurance reform 42
 - temporary movement of providers 171
 - waiting times/lists 259, 261
- not-for-profit organizations 257, 298, 314, 350
- nursing home quality of care 307–14
 - bed shortage 311
 - chain ownership 309
 - Compare report card 314
 - CON (certificate of need) 309, 311–13
 - demand-side 308–9
 - literature review 311–14
 - market characteristics 308–11, 313
 - market competition 309
 - Medicaid payments 307–8, 309–14
 - Medicare payments 307, 308, 309–13
 - occupancy rates 309, 310, 311, 313
 - OSCAR reporting system 310
 - ownership type 310, 311, 313–14
 - productivity 360–61, 364
 - publicizing quality information 314
 - supply-side 309
- Nussbaum, M. 415, 416–17, 418, 419, 420
- nutrition 16, 53–4, 57, 181, 184, 252
 - food fortification 54, 525
 - see also* diet; food
- Nyman, J.A. 93–101, 103–4, 107, 117, 125, 310, 311, 312, 485
- Oaxaca-type decomposition 179, 180–81, 183, 184, 186–7
- obesity 10, 11, 12
 - behavioural theory 74–5, 77
 - consequences of 75–6
 - determinants 70–71
 - economics theories 71–5
 - economics of 70–78
 - food addiction 74, 75
 - health implications 75–6
 - labour market effects 76
 - Medicare/Medicaid 76
 - neoclassical case for intervention 77
 - neoclassical theory of weight 71–4, 75
 - over-eating 36
 - public policy and 76–8
 - snack foods 75
 - trends 70–71
 - weight loss 76, 78
 - young people 60, 64
 - see also* diet; weight
- O'Brien, B. 389, 395, 429, 430, 534, 540, 564, 573
- obstetrics *see* pregnancy
- O'Donnell, O. 27, 179–89, 192, 207, 209
- OECD 159, 168, 259
 - equity in Asian health system 203, 209
 - macroeconomic effects on mortality 8, 10
 - public health expenditure 125, 219, 322
 - see also individual countries*
- older workers 290
 - health and work of 24–32
- Olmstead, T.A. 81–8
- Olmstead decision 309
- OLS model 473, 474, 476, 478
- Olsen, J.A. 125, 407, 409, 411, 425, 429, 463
- Oman 49
 - GATS commitments 167
- ophthamology 199, 396
- opium 82, 86
- opportunity cost 336, 429, 464, 553, 592
 - of caregiver's time 319, 322
 - decision rules and 528, 531, 534–5
 - priority setting 576, 577, 583
- oral surgery (waiting times) 261
- organ transplants 130, 515
- orthopaedics (waiting lists) 261
- OSCAR reporting system 310
- osteoarthritis 76, 335, 383, 390
- osteoporosis 486
- outpatient services 42, 85, 140, 146, 154, 362
 - Asia 206, 208, 212

- consumption (equity) 198–201
- primary care 282, 285
- pain/pain relief 81, 252, 422
- Pakistan
 - child health and maternal services 207
 - child mortality 205
 - contracting-out 252
 - GATS commitments 167
- Palmer, N. 250–57
- Panama, GATS commitments 167
- parental pressure 60–62, 64–6
- patient values 398
- patients 297, 443
 - cost-sharing 116–17, 118–19, 129, 130
 - physician as agent 271–8
 - preferences 437
 - satisfaction 277, 286, 345
- Pauly, M.V. 96, 97, 103, 115, 116, 123, 124, 236, 363
- 'pay-for-performance' 256, 276–8, 280–84, 286, 295, 298–301, 303, 311, 356
- payer-provider negotiation 231–7
- payments
 - of GPs 284–6
 - home health care 320–21
 - nursing homes 307–8, 309, 310, 311–13
- payments, unofficial (in low- and middle-income countries) 154–61
 - additional services enhancements 157
 - child mortality and 157
 - consumer choice of quality 159
 - contracting approaches 159
 - corruption approaches 154, 157–8, 160, 161
 - drugs payments 154–5
 - dual practice 155, 159, 160
 - extent/nature of 154–7
 - future research 160–61
 - 'inexit' theory 156
 - modelling (approaches) 157–9
 - policy implications 160–61
 - 'Robin Hood' effect 157
 - wage levels and 159, 160, 161
 - willingness to pay 156
- Peacock, S.J. 275, 276, 576–83
- peer pressure 60–62, 64–6
- penicillin 49
- pensions 24, 32, 126
- performance
 - based bonuses 299, 300, 301
 - based incentives 255–6, 299
 - delivery and equity (Asia) 212–13
 - indicators 342, 345, 347, 352–3
 - pay-for *see* 'pay-for-performance'
 - productivity analysis 359–65
 - performance of health care organizations,
 - measuring 341–8
 - adverse selection 345–6, 348
 - agent generated 345–6
 - conjoint analysis 344
 - gaming 345–6, 351, 352, 354
 - joint outputs 347–8
 - measurement instruments 34, 345–6
 - moral hazard 347–8
 - mortality rates 347
 - organizing framework 342–3
 - parametric frontier methods 344
 - patient satisfaction 345
 - principal-agent model 341–2, 343–4, 345, 346–7, 348
 - principal's objectives 343–4
 - ratchet effect 346
 - targets and rewards 345–6, 347–8
 - waiting times 347
 - performance measures in health care systems
 - 342, 350–57
 - behavioural impact 355–6
 - construction and use of 353–6
 - evidence (on use/impact) 355–6
 - gaming 350, 351, 353, 354
 - information (impact) 355–6
 - information (use of) 355
 - intrinsic motivation 351
 - not-for-profit organization 350
 - outcome impact 355–6
 - PCPA 353
 - process and outcome measures 351–3
 - PROMS 355
 - public disclosure 351
 - rationale for 351–3
 - special features 350–51
 - waiting times 352, 356, 357
 - person trade-off (PTO) 397
 - personal medical care 46–7
 - personal responsibility 192, 411
 - see also* self-assessed health (SAH)
 - pertussis 54
 - Peru 53
 - unofficial payments 158
 - Pharmacare 118, 119
 - pharmaceuticals 515, 534, 586
 - advertising *see* advertising, direct to consumer (DCA)
 - economic evaluation 586–93
 - innovation, remuneration and 119–20
 - product financing 235, 237
 - see also* drugs/drug use; prescription drugs
 - pharmacotherapy 303
 - Philippines
 - child health and maternal services 206–7

- child mortality 205
- equity in health care 205, 206–7
- health care financing 210, 211
- health services trade 167, 171
- poverty and health expenditure 211
- temporary movement of providers 171
- Philipson, T.J. 62, 70–78, 115, 120, 309
- physical inactivity 10
 - see also* exercise
- physical restraints 311–12
- physician clinical performance
 - assessment (PCPA) 353
- physician as patient's agent 271–8
 - advertising (impact) 330
 - agency theory 271–3
 - capitation and 273–4, 276–7, 278
 - economic behaviour 271–7
 - economic theories 271–4
 - fee-for-service 273, 274–6, 278
 - implications 277–8
 - pay-for-performance 276, 277–8
 - salary and 273–4, 276–7, 278
 - welfare implications 272
- physician productivity measurement 361–2
- Pinto, J.L. 371–80, 383, 411, 437
- pneumonia 46, 54, 225, 314, 486
- Poisson regression model 145, 146, 147, 476, 478
- Poland
 - GATS commitments 167
 - health services trade 167, 169
 - unofficial payments 155
- polio 54
- pollution 11, 12, 431
- Polsky, D. 151, 464, 490–500, 540, 543
- pooled data 6–11
- Portugal 87
 - child mortality 50
 - EuroWill project 431
 - public-private partnership 237
- poverty 47–8, 181, 283–4, 297, 418
 - globalization and 172
 - health care expenditure and (Asia) 207, 209–11, 213
 - prescription drug insurance 118–19
 - reduction 49, 86, 172
 - waiting times and 589
- pravastatin 589
- preference-based measures of health 395–403
 - data preparation 398–9
 - future research 402–3
 - health state classifications 395–9
 - item generation/selection 397
 - mapping 401
 - ME (magnitude estimation) 397
 - modelling 399–401, 402
 - patient values 398
 - PTO (person trade-off) 397
 - respondents 398
 - SF-6D 395, 396, 397, 401
 - SG 383–4, 385, 386–7, 390, 397
 - specificity 396
 - TTO 383–4, 385, 386–7, 390, 397
 - valuation technique/data 397–9, 402
 - VAS 397
 - see also* economic evaluation (distributional judgements); health-related quality of life (HRQL) assessment
- preferences 406, 437, 443, 444, 447
- pregnancy 54, 124, 206, 207, 521
 - childbirth 40, 275
 - maternal mortality 251
 - neonatal deaths 8, 9, 10, 56
 - obstetrics 40
 - prenatal care 11, 256, 437–8
 - unwanted 60
- prescription drugs 271, 286
 - advertising (DCA) 329–36
 - drug plan remuneration 119–20
 - insurance and reimbursement 114–20
 - labelling claims 396
 - lifestyle drugs 118
 - moral hazard 116–19
 - non-medical use 82
 - patient cost sharing 118–19
 - prior authorization (PA) 117
 - unofficial payments 154–5
- preventive medicine 252, 256, 277, 426, 512
- prices
 - as attributes 438–9
 - elasticity 61, 107–8, 109–10, 111, 128, 134, 135, 297, 333
 - fixed 222–3, 244, 245–6, 247
 - pressure 60–64
 - proxy 438–9
 - regulation 222–3
- primary care 276, 300, 302
 - capitation *see* capitation system
 - contracting-out 252, 254, 255, 257
- principal-agent model 104, 148, 237, 241–2, 289, 330–31
 - performance 341–2, 343–4, 345, 346–8
 - physician as patient's agent 271–8
- prioritization, waiting time 264, 266
- priority setting methods in health services 429, 576–83, 590–91
 - case study 579, 580
 - challenges 583
 - ethics and economics (balancing) 582–3

- exercise (steps) 577–9
 - MCDA 579–81, 582
 - objectives/criteria 580–81, 583
 - PBMA 576–9, 580, 581, 583
- private finance initiatives 237
- private sector 251, 265
- process/product innovation 360
- productivity analysis in health care 344, 346, 359–65
 - DEA 363, 364
 - duality theory 359
 - economies of scale/scope 360, 361
 - efficiency-based methods 360–62
 - FDH 363–4
 - financial incentives 362
 - health organizations 361
 - inefficiency measurement 362–4
 - integrated frontier methods 364
 - non-parametric frontier methods 363
 - nursing homes 360–61
 - parametric frontier methods 363
 - patient panel size 361–2
 - physicians 361–2
 - process improvement 364
 - RVUs (relative value units) 361
 - technical efficiency 360
- profit-maximization 250, 284, 294
- programme budgeting and marginal analysis (PBMA) 536, 576–81, 583, 587–8
 - case study 579, 580
 - steps (priority setting) 577–9
- Progressa-Oportunidades programme 55–6
- Propper, C. 225, 236, 247, 259, 262, 282, 303, 341, 343, 348, 350–57, 359, 447
- prospect theory 374–5, 428
- proton pump inhibitors 336
- provider attitudes 330–31
- providers, temporary movement of 170–71
- PSID 17, 19
- psychometric measures 383–90, 395–7, 399, 401
- psychosocial health 198, 201
- psychotherapy 303
- public-private partnerships 234–5, 237
- public health interventions 421
 - children in developing countries 46–57
 - cost-effective 55–6
 - demand-oriented 55–6
 - disease control 47, 49, 52, 53–5, 56
 - historical role 48–52
 - immunization 52, 54–5, 57
 - individual vs. 46–7
 - market failures 47–8
 - modern evidence base 52–6
 - mortality decline 48, 49–51
 - obesity and 76–8
 - supply-oriented 52–5
- public interest groups 330
- Punjab
 - child mortality 49
 - health care financing 210
- punishment, performance and 343
- QALY (quality-adjusted life year) model
 - contingent valuation 425–7, 430, 432, 437
 - cost-effectiveness analysis (clinical trials) 544, 545
 - cost-effectiveness analysis (decision rules) 506–11, 513, 531, 533–5
 - cost-effectiveness analysis (future costs) 481, 482, 485–7
 - cost-effectiveness analysis (principles/practice) 516, 523
 - decision-making 552–3, 557–8, 590, 592–3
 - economic evaluation (distributional judgements) 406–13
- HIV 486
- health utility measure 371, 372–5, 377–8, 379, 380
- maximization (weighted) 412–13
- Principle Q challenged 407–10
- Principle Q supported 410–12
- testicular cancer 373
- value of 406, 407–10
- Qatar, GATS commitments 167
- quality
 - assurance (nursing homes) 310–11
 - consumer choice of 159
 - health services 284–5
 - hospital competition and 220, 221, 223–4, 225
 - reports 295, 311, 355, 356
- quality of care 276, 334, 353
 - in mental health 297–305
 - in nursing homes *see main entry*
 - risk adjustment 292–4
- quality of life, health-related (HRQL)
 - see* health-related quality of life (assessment)
- Quality and Outcomes Framework (QOF) 281, 283, 284, 304, 356
- Quality of Well Being scale 385, 387, 388
- radiation therapy 498
- radiology 286
- Raikou, M. 246, 463–70, 540
- RAND Health Insurance Experiment (HIE) 97, 109–11, 128, 148, 297, 473, 477–8
- Rannan-Eliya, R. 192, 203–14
- Rasch analysis 398

- ratchet effect 346, 354
- rational addiction model 60, 62
- rationing 130, 263–6, 292–5
- reference points 428
- reference pricing 118, 119
- referral rates 260, 285–6
- regulation, price 221–3
- reimbursement 107, 281, 298, 311, 550
 - hospital competition 221, 226
 - prescription drug insurance 114–20
- renal disease 9, 107, 486, 515, 589
- rent-seeking 156, 160, 213, 227, 242, 246
- resource-poor settings (contracting-out health service provision) 250–57
- resource allocation 251, 283, 398, 426, 487, 515, 577, 579, 587
 - decision rules 528, 532–3, 534
 - distributional judgements 407, 408
- respiratory disorders 76, 199, 206
- retirement 24, 26, 28, 30, 201
 - early 16, 25, 29, 31–2, 324
 - see also* ageing
- rewards 241, 342, 343
 - targets and 345–8, 351, 353, 356, 357
- rheumatoid arthritis 114
- rhinitis 391
- Rice, N. 15–22, 28, 189, 347
- Rice, T. 103, 112, 141, 271–8, 281
- risk
 - assessment 123–5, 127, 129–31
 - aversion 16, 94, 96, 103–6, 108, 114, 129, 264, 343, 373
 - factors 524–5, 564–72
 - first-order uncertainty 565–6, 568–71
 - health insurance and 105–6, 123–4, 126–7, 129–31
 - neutrality 372–3, 374
 - selection 126, 127, 129–30, 220, 236
 - sharing 282, 589–90
- risk adjustment 281, 286–7, 303, 352, 353, 498–9
 - adverse selection 291–2, 294
 - age factor 289, 290, 292
 - conventional 289, 290–92, 293, 294
 - cost-effectiveness analysis 518–21
 - group access 290–91
 - health insurance 124, 126–7, 129
 - heart disease 425
 - individual access 290–91
 - mental health 302, 303
 - optimal 286–7, 289–95
 - practice of 294–5
 - problems addressed 290–94
 - quality of care 292–4
 - social health insurance 124, 126–7, 129
 - transport safety 425
 - see also* health plans
- Robert Wood Johnson Foundation 300, 302
- Roberts, J. 251, 372, 383, 385, 387, 395–403, 437
- ‘Robin Hood effect’ 157
- Robinson, J.C. 139, 276, 282, 301
- Romania, health services trade 169
- rotavirus 54
- ‘rotten kids’ model 62
- Rowen, D. 372, 383, 395–403, 437
- Rubin, D.B. 41, 464, 465, 466, 470, 491, 494, 495
- Ruhm, C.J. 5–12, 65
- Russia
 - performance measurement 346
 - smoking 63
 - unofficial payments 160
- Rwanda, GATS commitments 167
- Ryan, M. 246, 272, 320, 344, 396, 426, 427, 430, 437–44, 447–8
- Saint Lucia, GATS commitments 167
- St Vincent, GATS commitments 167
- salaries 26, 76, 158, 324
 - capitation and 273–4, 276–8, 281
 - wage levels 159, 160, 161
- sanitation 46, 55, 181, 522
- SARS virus 172
- Saudi Arabia 49
 - health care quality 169
- Scandinavia
 - hospital choice 221
 - see also individual countries*
- schizophrenia 119, 303
- Schoenbaum, M. 276, 297–305
- Scotland 262, 283, 356, 443
- screening programmes 10, 46, 283, 302, 511, 520
 - cancer 195, 505, 590
 - Chlamydia 444
 - choice task 437–8
 - cystic fibrosis 436
- Sculpher, M.J. 463, 516, 524, 534, 540, 547, 550–61, 564, 573, 591
- selection bias in observational data 304, 490–500, 571
 - addressing 493–9
 - ATE 492–3, 494, 496, 497, 498
 - breast cancer example 490–91, 498–9
 - covariate adjustments 494, 495, 499
 - definition 493
 - evaluation and 491–3
 - hidden biases 493, 494–5, 496–500
 - illustrative examples 490–91

- matched sampling 495
- model-based covariated adjustment 494, 495
- model of treatment choice 492
- overt biases 494
- parameter of interest 492–3
- propensity matching 494–5, 499
- study designs 493–4
- ‘selective contracting’ 221, 252
- self-assessed health (SAH) 18–22, 26–30
 - cultural differences 27–8
 - personal responsibility 192, 411
- Sen, A. 415, 416–18, 419, 443
- Senegal
 - contracting-out 252
 - GATS commitments 167
- senior citizens *see* ageing; elderly
- sensitivity analysis 486, 488, 496, 524
- service-level selection 292–3, 294, 295
- services 157, 247, 307–8
 - cross-border supply of 168–9
- sexual behaviour
 - Chlamydia screening 444
 - erectile dysfunction 118
 - STDs 60, 66–7, 444
 - substance abuse and 40, 66–7
 - unsafe 522
 - young people 60, 65, 66–7
- see also* HIV/AIDS
- Shackley, P. 246, 425–32, 435–7, 533
- shadow price 294, 533, 592
- SHARE data 263, 318, 321
- shared care 302
- shirking 227–8
- ‘shopping spree’ problem 507–8, 510–13
- Siciliani, L. 233, 240, 245, 247, 259–66, 283
- side-effects 329, 330, 545
- Sierra Leone, GATS commitments 167
- simvastatin 545–6
- Sindelar, J.L. 81–8
- skin complaints 199
- sleep apnoea 76
- sleep patterns 11
- Slovak Republic, GATS commitments 167
- Slovenia, GATS commitments 167
- Smith, P.C. 221, 259, 260, 261, 303, 341–8, 354, 359, 553
- Smith, R. 164–73, 415–22
- smoking 10, 36–7, 334, 417
 - body weight and 64
 - causal effects 41, 43
 - cost-effectiveness analysis 516–20, 521, 522, 524–5
 - mortality and 417–18
 - price 41, 60, 61–2, 63, 64
 - young people 60, 61, 62–3, 64–5, 67
- snob effects 61
- social health insurance 135
 - administrative costs 127
 - comparative outcomes 128–30
 - competitive 126–7, 128
 - cream-skimming 124, 125, 126, 129
 - economics of 123–31
 - efficiency reasons 123–4
 - equity reasons 124
 - future challenges 130–31
 - government re-election and 125, 126
 - health redistribution 125–6
 - international purchasing 131
 - medical care redistribution 125
 - moral hazard 126, 128–9
 - non-insurable loss 127–8
 - optimal contract (design) 127–8
 - public choice reasons 125–6
 - public health insurance 127, 128
 - rationing 130
 - risk assessment 123–5, 127, 129–31
 - risk selection 127, 129–30
 - supply of 126–7
 - technological change in medicine 131
 - ‘umbrella’ policies 130–31
 - wealth redistribution 125
- social isolation 12
- social justice 410, 415, 422
- social security 24, 31, 42, 211–12, 321
- social welfare function 124, 463, 572–3, 578
- socioeconomic status (SES) 16–18, 19, 20, 22, 225, 254, 263, 409
 - equity in consumption 198, 200–201
 - health inequalities 183, 185–6, 411
 - survey data 198, 200
- Somanathan, A. 192, 203–14
- South Africa
 - contracting-out 252, 255, 256, 257
 - GATS commitments 167
 - health services trade 167, 169
 - temporary movement of providers 171
- South America
 - alcohol and tobacco use 516–19
 - child mortality 51
 - unofficial payments 160
 - see also individual countries*
- South Korea
 - equity in health care 206
 - health care financing 210
 - health care utilization 206
 - poverty and health expenditure 210
- Southeast Asia 49
 - see also individual countries*
- Spain
 - hospital competition 220

- informal care 318
- mortality 8
- smoking 63
- Sri Lanka
 - child mortality 49, 205
 - equity in health care 203, 204–8
 - FDI 170
 - government social spending 207, 208
 - health care financing 210, 212
 - health care utilization 205, 206
 - health inequalities 204
 - poverty and health expenditure 210–11
 - tax systems 212
- starvation 416
- state dependence 18–19, 25, 26, 324
- statins 333–5, 505, 521, 545–6
- Stinnett, A. 535, 541, 551, 572
- Street, A. 221, 303, 341–8, 356, 359
- Street, D.J. 437, 439, 440, 447–57
- streptomycin 49
- stress 11
- strokes 76, 388–90, 515
- subsidies 207–8, 251–2, 254, 534
- substance use *see* drugs/drug use
- suicide 5, 7, 8, 9, 60
- supplier-induced demand 40
- supply 126–7, 168–9, 221–2, 309, 320
- SURE approach/framework 544–5
- survivor costs 482
- Sutton, M. 192–201, 283, 397
- Swaziland, GATS commitments 167
- Sweden
 - GATS commitments 167
 - health services trade 167, 171
 - hospital competition 220, 226
 - informal care 318
 - medical costs 484, 486
 - priority setting 576
 - Public Employment System 27
 - public health expenditure 219
 - temporary movement of providers 171
 - unemployment 27
- Switzerland
 - alcohol prices 63–4
 - bargaining in health 233
 - child mortality 50
 - GATS commitments 167
 - health insurance 112
 - health plans 136, 141, 295
 - hospital competition 219, 220, 226
 - social health insurance 127
- Taiwan
 - cross-border supply of services 168
 - equity in health care 203–6, 209, 214
 - health care financing 209, 210, 212
 - health care utilization 205, 206
 - poverty and health expenditure 211
 - social insurance system 212
- Tajikistan, unofficial payments 158
- Tan-Torres Edejer, T. 515–26
- Tanzania
 - health workers 53
 - unofficial payments 161
- taxation 77–8, 123–4, 345, 429
 - Asia 209, 211–13
 - subsidies 97, 114, 126
- technology 131, 551–3
 - assessment reports 560, 586
- testicular cancer 373
- tetanus 54
- Thailand
 - equity 204, 206–7, 208, 209
 - government social spending 207, 208
 - health care financing 209, 210, 212
 - health care utilization 206
 - health services trade 169
 - poverty and health expenditure 211
 - tax systems 212
- Thompson, R. 154–61, 213
- thyroid problems 119
- time preference rates 16, 17
- Torrance, G.W. 383, 385–6, 390, 396–7, 419
- tourism 169, 172
- trade in services *see* globalization
- traffic deaths 7, 8, 9, 10, 12, 60, 66
 - safety policy 425, 430
- transaction costs 257, 304, 341, 583
- transition countries 213
 - unofficial payments 154–5, 159
 - see also individual countries*
- treatment
 - ATE 41–2, 43–4, 151, 492–4, 496–8
 - on the treated (TT) effect 42, 43, 44
- Trinidad and Tobago, GATS commitments 167
- Trivedi, P.K. 144–52, 192
- Tsuchiya, A. 125, 396, 397, 406–13
- tuberculosis 54, 251, 252, 515, 522
- Turkey
 - GATS commitments 167
 - unofficial payments 155, 156
- two-part model 145–6, 147, 148, 150
- typhoid 55
- Uganda
 - contracting-out 252
 - health care workers 53
 - unofficial payments 155
- UK 20, 573
 - bargaining in health care 233–6, 237

- BHPS 17, 18, 19, 21, 420
 capability approach 417, 418, 419–22
 child mortality 50
 contracting-out 250, 253
 cost-effectiveness analysis 530, 534, 536
 day case treatment 198–201
 DFID 250, 254
 District Health Authorities 225, 282
 drug-related crime 81
 equity in health care consumption (England)
 198–201
 ethnicity 198, 200, 201
 EuroWill project 430, 431
 financial incentives 299, 300
 fixed price contracts 245
 GP consultations 198–201
 GP fundholding 118, 225, 236, 260, 262,
 277–8, 282
 health insurance 93, 115
 health resource group 245, 247
 health services trade 169, 171
 hospital competition 219, 220, 224–6
 ICEPAP 421–2
 in-patient stays 198–201
 informal care 324
 NHS *see main entry*
 NICE *see main entry*
 OCAP-18 420–21
 older workers 29, 31
 out-patient visits 198–201
 pay-for-performance 277–8, 281
 PBMA 577, 578, 587–8
 performance measurement 299, 351, 352,
 353, 354, 355, 356
 pharmaceutical evaluation 443, 534, 586,
 587, 589–91, 592, 593
 primary care 280–87
 Primary Care Trusts 282–3
 priority setting 576, 577, 578
 QOF 281, 283–4, 304, 356
 quality assessment 386, 387
 smoking 63
 social security 31
 technology assessment 550, 552, 560–61,
 586
 temporary movement of providers 171
 transport safety policy 430, 432
 waiting times/lists 259, 260, 262, 263
 willingness to pay 430, 432
 ulcers, pressure 311, 312, 313
 UN
 Human Development Index 417
 Millennium Development Goals 251
 uncertainty 15, 94, 241, 280–81, 342–3, 362,
 374, 485
 cost-effectiveness analysis 516, 524, 539–40,
 544, 547
 first-order 565, 566, 568–9, 570–71
 parametric 565, 569, 570, 571
 see also decision-making with uncertainty
 (value of information)
 unemployment 6, 7, 8, 9, 10, 16, 171
 Germany 30
 insurance 29
 Sweden 27
 UNICEF 46
 unofficial payments *see* payments,
 unofficial (in low- and middle-income
 countries)
 Uruguay, child mortality 51
 Uruguay Round 165
 USA 20, 47, 55, 65, 457, 586, 587, 591
 advertising (DCA) 329–30, 331–6
 any willing provider 233–4, 237
 bargaining in health care 233–5
 BBA 294, 308
 Boren Amendment 308
 calorie consumption 71, 72
 capitation 274, 280, 290, 292
 ‘cash and counselling’ 321
 child mortality 10, 48–9, 51, 56
 Diagnosis Related Groups 222, 223
 drug-related crime 81, 83, 86, 87
 drug subsidies to seniors 115
 drug use 81, 82, 85–6
 FDA 564, 573
 financial incentives 298–302, 303–5
 fixed price contracts 245
 GATS commitments 167–8
 Health Care and Education Reconciliation
 Act 300
 health care use 144, 146, 148
 health insurance 31, 93, 96–101, 109–10,
 111, 144, 290
 health plans 134–5, 140–42, 144, 290, 291–3,
 294–5, 299
 health services trade 167–9, 171
 HEDIS 299
 height of men 48, 52
 HMOs 118, 225, 231, 235–6, 274, 276–7,
 283, 299, 430
 hospital competition 219, 220, 222, 224–5,
 227
 informal care 318, 320–21, 322, 324
 IPA 274
 legal drinking age 82
 life expectancy 488
 macroeconomic effects on mortality 5, 6, 10
 managed care 134, 141, 221, 224, 235
 marijuana use 81

- Medicaid *see* Medicaid
 medical costs 481–2, 484, 486, 488
 Medicare *see* Medicare
 MEPS 135
 mortality 10, 48, 49, 51, 56, 354
 National Health Interview Survey 70–71
 National Institutes of Health 564
 NHCPI 301, 303, 304–5
 NSDUH 82
 nursing home care 307–14
 obesity 70–72, 73, 76, 78
 OBRA 87, 310
 older workers 24, 27–8, 30, 31
 Olmstead decision 309
 OSCAR reporting system 310
 PA schemes 117
 Patient Protection and Affordable Care Act 309
 Parity Act 300–301
 pay-for-performance 277, 281–2, 283
 payment rate freezes 275
 PBMA 536
 performance measurement 299, 348, 353–6
 PPS 308, 309, 313
 prescription drug insurance 115, 117–19
 Primary Care Physicians 280
 priority setting 576
 productivity analysis 364
 PSID 17, 19
 quality assessment 386, 387
 RAND HIE 97, 109–11, 128, 148, 297, 473, 477–8
 retirement 24
 self-reported disability 27–8, 30
 smoking 61, 63
 social security 31, 96, 321, 488
 temporary movement of providers 171
 USAID 255
 Washington Panel 398
- vaccination *see* immunization
 van Doorslaer, E. 21, 22, 179–89, 192, 193, 203, 205, 210, 211
 Van Houtven, C.H. 308, 309, 318–25
 Vanness, D.J. 493, 550, 563–73
 Venezuela, unofficial payments 158
 Venkatapuram, S. 415–22
 Vietnam
 - child and maternal services 206–7
 - child malnutrition 181
 - child mortality 182, 205
 - equity in health care 205–7, 208
 - government social spending 208
 - HAZ scores 181, 184–5, 186, 187–8
 - health care financing 213
 - health care use 147
 - health inequalities 181–2, 184–8
 - poverty and health expenditure 210–11
- Viney, R. 437, 439–40, 447–57
 Vioxx 335
 vitamin A 54
- Wagstaff, A. 20, 21, 126, 179–89, 192, 193, 197, 203, 205, 210–11, 251
 waiting lists 259–66, 356
 - globalization and 169, 172
- waiting times 259–66, 282, 284, 356
 - co-payments 264
 - competition and 223–4, 225, 262
 - endogenous capacity 265–6
 - financial penalties 259
 - normative analysis 263–6
 - policy implications 266
 - positive analysis 259–63
 - prioritization 264, 266
 - private sector 265
 - rationing 263–6
 - targets 260, 262, 352
- Wales 561, 578, 586
 water quality 52, 54–5, 179, 181, 522
 weight
 - appearance and 76
 - behavioural theory 74–5, 77
 - BMI 64, 70–71, 73–4, 78
 - capital investment model 72
 - food prices and 72–4
 - income and 73
 - loss 76, 78
 - neoclassical theory 71, 72–4, 75
 - smoking and 64
 - technology and 73
 - see also* diet; obesity
- Weinstein, M.C. 481, 505–14, 528, 529, 530, 531, 541, 544
 welfarism 419, 422, 487
 well-being 415, 416, 420
 Williams, A. 22, 130, 193, 195, 197, 344, 407, 528, 533, 536, 590
 Williams, J.A. 226, 297–305
 willingness to pay 100, 156, 344, 407, 425–32, 510, 533, 539, 553, 592–3
 - contingent valuation 425–32, 435–6
 - discrete choice experiments 438–9, 441, 444
 - decision-maker's dilemmas 427–32
 - prescription drugs 114, 116
 - social health insurance 125, 131
- Wilson, D. 247, 303, 341, 343, 348, 350–57, 359
 work 11
 - health and 24–32

- informal care and 323–4
 - see also* employment
- workforce 11, 227
 - in healthcare 53, 171, 251, 307, 310–11
 - older 24–32, 290
- World Bank 411, 417, 522
 - World Health Organization 46, 52–3, 55, 60, 86, 125, 165, 168, 204, 250, 344
 - CHOICE project 521, 522, 523, 524
 - health definition 396
 - Health InterNetwork 168
 - International Classification 396
 - league tables 348, 524
- World Trade Organization 63, 165, 167
- young people
 - alcohol use 60, 62–4, 65, 66, 67
 - death (leading causes) 60
 - health behaviours 60–67
 - maternal employment 65
 - NLSY 65, 73
 - obesity 60, 64
 - peer and parental pressure 60–62, 64–6
 - price pressure 60–64
 - ‘rotten kids’ model 62
 - sexual behaviour 65, 66–7
 - smoking 43, 60, 61–3, 64, 65, 67
 - suicide 60
 - traffic deaths 60, 66
- Zambia
 - GATS commitments 167–8
 - hospital competition 226
 - zanamivir 551–2, 555, 557
 - zero tolerance laws 66–7
 - Zweifel, P. 108, 123–31, 146, 319, 444

